Apr 16, 2026
R&D teams are starting to advance AI capabilities faster
than they can translate them into measurable business value,
creating mounting friction between scientific progress and
operational reality. In this episode, Aziz Nazha, Global Head of AI
Innovations Institute at Incyte Pharmaceuticals, examines how
culture, talent, infrastructure, and expectation‑setting determine
whether AI meaningfully improves drug discovery and development. He
highlights the practical shifts required — from redesigning
workflows to disciplined upskilling and targeted validation cycles
— to ensure AI adoption accelerates cycle times rather than getting
stalled by organizational bottlenecks. This episode is sponsored by
Deloitte. Learn how brands like Deloitte work with Emerj
and other Emerj Media options at go.emerj.com/partner